Vaccines (Jul 2021)

In Vivo Production of HN Protein Increases the Protection Rates of a Minicircle DNA Vaccine against Genotype VII Newcastle Disease Virus

  • Zhannan Wang,
  • Xiaohan Zhao,
  • Ying Wang,
  • Chao Sun,
  • Ming Sun,
  • Xingyun Gao,
  • Futing Jia,
  • Chenxin Shan,
  • Guilian Yang,
  • Jianzhong Wang,
  • Haibin Huang,
  • Chunwei Shi,
  • Wentao Yang,
  • Aidong Qian,
  • Chunfeng Wang,
  • Yanlong Jiang

DOI
https://doi.org/10.3390/vaccines9070723
Journal volume & issue
Vol. 9, no. 7
p. 723

Abstract

Read online

The Cre-recombinase mediated in vivo minicircle DNA vaccine platform (CRIM) provided a novel option to replace a traditional DNA vaccine. To further improve the immune response of our CRIM vaccine, we designed a dual promoter expression plasmid named pYL87 which could synthesize short HN protein under a prokaryotic in vivo promoter PpagC and full length HN protein of genotype VII Newcastle disease virus (NDV) under the previous eukaryotic CMV promoter at the same time. Making use of the self-lysed Salmonella strain as a delivery vesicle, chickens immunized with the pYL87 construction showed an increased serum haemagglutination inhibition antibody response, as well as an increased cell proliferation level and cellular IL-4 and IL-18 cytokines, compared with the previous CRIM vector pYL47. After the virus challenge, the pYL87 vector could provide 80% protection compared to 50% protection against genotype VII NDV in pYL47 immunized chickens, indicating a promising dual promoter strategy used in vaccine design.

Keywords